A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
NCT07465653
This study is recruiting at 5 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Heart Failure With Reduced Ejection Fraction
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Novartis Pharmaceuticals
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 5
- Synergy Healthcare · Bradenton, FL
- Nature Coast Clinical Research LLC · Inverness, FL
- Jacksonville Center for Clinical · Jacksonville, FL
- Inpatient Research Clinical LLC · Miami Lakes, FL
- Flourish Research · Winter Park, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.